No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
DGX Quest Diagnostics
- 144.110
- +0.610+0.43%
Close Jul 12 16:00 ET
- 144.530
- +0.420+0.29%
Post 18:19 ET
16.01BMarket Cap19.40P/E (TTM)
145.220High143.485Low581.88KVolume144.170Open143.500Pre Close84.06MTurnover0.53%Turnover Ratio19.24P/E (Static)111.09MShares145.22052wk High2.49P/B15.88BFloat Cap116.96952wk Low3.59Dividend TTM110.18MShs Float163.893Historical High2.49%Div YieldTTM1.21%Amplitude2.596Historical Low144.466Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
What Awaits Quest Diagnostics (DGX) in Q2 Earnings Release?
Quest Diagnostics to Purchase Outreach Lab Assets From Health System OhioHealth
Citi Upgrades Illumina, Quest, Agilent to Buy, Downgrades Avantor
Express News | Quest Diagnostics Inc: Financial Details of Transaction Were Not Disclosed.
Express News | Quest Diagnostics to Acquire Outreach Laboratory Services of Ohiohealth
Express News | Quest Diagnostics Inc : Citigroup Raises to Buy From Neutral; Raises Target Price to $165 From $145
Comments
$Quest Diagnostics(DGX.US$ PathAI + Invigorate + stable finance + qualified management team + decent PE.
Will it dominate pathology and cancer diagnosis with AI in the future? Worth noting.
Will it dominate pathology and cancer diagnosis with AI in the future? Worth noting.
4
Quest Diagnostics' consistent ROCE and increased capital employed over the past five years suggest steady reinvestment at good returns. This trend, reflected in the stock's strong performance, is expected to continue.
The acquisition aligns with Quest's strategy to grow through accretive outreach laboratory acquisitions and expands its ability to serve providers and patients in Ohio and Pennsylvania.
The CEO of Quest Diagnostics, Jim Davis, believes Yuri Fesko's deep medical expertise and patient-care advocacy will greatly contribute to the company's strategic decisions. His appointment especially bolsters Quest's efforts to improve customer experiences via diagnostic innovations.
Quest Diagnostics shows favorable metrics with robust reinvestment strategies. Significant earnings growth and an anticipated rise in future ROE, despite a higher payout ratio, hint at other growth factors.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
